Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (Prince of Wales Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (Prince of Wales Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical developmen
9 min read
Itruvone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Itruvone: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Sildenafil/Metformin/Leucine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Sildenafil/Metformin/Leucine: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key r
9 min read
Acloproxalap Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Acloproxalap: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Umbilical cord-derived mesenchymal stromal cells(University of Louisville) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Umbilical cord-derived mesenchymal stromal cells(University of Louisville): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, I
9 min read
Tongfengkang Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Tongfengkang Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Mini-FMT(Nanjing Medical University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Mini-FMT(Nanjing Medical University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, a
9 min read
Onatasertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Onatasertib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Menstrual blood derived mesenchymal stem cells (Innovative Precision Medicine Group) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Menstrual blood derived mesenchymal stem cells (Innovative Precision Medicine Group): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical deve
9 min read
Zibotentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Zibotentan: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ONO-2020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ONO-2020: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MG-O-1001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
MG-O-1001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.